Fig 3.
The effect of any TOP2A abnormality (either TOP2A deletion or TOP2A amplification) on disease-free survival for high-level HER2-amplified instances (HER2/CEP17 ratio > 4.0). Similarly, no significant differences in overall survival were observed for TOP2A and HER2 coamplified instances, and neither overall nor disease-free survivals were significantly different when the analysis was segregated for TOP2A deletion or TOP2A amplification within the HER2-amplified group.